A subsidiary of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter, Inc. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Learn more about Beckman Coulter's cardiovascular disease solutions at About Beckman Coulterīeckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory's role in improving healthcare outcomes. Anagh Vora, chief medical officer, Beckman Coulter. This is an important biomarker in the diagnosis of heart failure (HF) and left ventricular dysfunction," said Dr. "BNP is a protein secreted by the ventricular musculature in response to volume or pressure overload on the heart. The speed and accuracy of the information a clinical laboratory delivers are critical to improving patient outcomes and reducing the cost of care. Clinical laboratories can support care for patients experiencing, or at risk for, cardiovascular disease. The cost of CVDs globally is estimated to rise to $1 trillion USD by 2030. Four out of five CVD deaths are due to heart attacks and strokes, while one third of these deaths occur prematurely in people under 70 years of age. Our panel of CVD assays supports advancing care for cardiac patients."Ĭardiovascular diseases account for an estimated 31% of all deaths worldwide and are the number one cause of death, globally killing ~17.9 million people each year. "Successful management of CVD means reducing the risk of adverse events by making the right decisions quickly.
These subsidiaries provide diabetes testing systems and urine analysis systems to medical institutions in North, Central and South America while also providing self monitoring blood glucose devices through drug store chains and other retailers."We are excited to add Access BNP to Beckman Coulter's line of high-quality cardiac assays and provide a streamlined customer experience for our many customers that use this critical assay," said Julie Sawyer Montgomery, president, Beckman Coulter. About ARKRAY's businesses in the AmericasĪRKRAY has 4 subsidiaries in the U.S., including U.S. mainly provides diabetes testing and urinalysis systems. and was established in 2010 as the American branch of ARKRAY, Inc. is a wholly owned subsidiary of ARKRAY, Inc. For over 80 years, they have been a leader in the field of in-vitro diagnostics. market.īeckman Coulter is a global company based in California which is expanding its business in 120 countries. urine analysis market and contribute to a reduction of labor and cost while continuing to respond to customer needs, elevating our presence and expanding our business in the U.S. Through this partnership of our two companies, ARKRAY hopes to streamline laboratory workflow for the U.S. This system will be exhibited at the 70th AACC 2018（The American Association for Clinical Chemistry" （July 29 to August 2, 2018, Chicago）. from the end of July 2018 as the " iQ Workcell". and for the sale of urine analysis systems.ĪRKRAY's fully automated urine analyzer " AUTION MAX AX-4030" will be paired to Beckman Coulter's urine sediment analyzer " iQ200 Digital Flow Morphology" and sold in the U.S. and Beckman Coulter Inc.（hereunder, Beckman Coulter）have signed a contract for a business partnership in the U.S. （Head office: Minneapolis, Minnesota, President: Kosuke Nakanishi）, has entered a contract with Beckman Coulter Inc.（Head office: Brea, California, President: Chris Riley）for a business partnership on urine analysis systems in the U.S.ĪRKRAY, Inc's. ARKRAY, a wholly owned US subsidiary of ARKRAY, Inc. ARKRAY, Inc.（Head office: Kamigyo-ku, Kyoto, President & CEO: Takeshi Matsuda）is pleased to announce that U.S.
0 kommentar(er)
